Literature DB >> 17568181

Aiding and ABT'ing Treatment for Glioblastoma.

Elaine Y Chung1, Michael Dews, Amit Maity, Andrei Thomas-Tikhonenko.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17568181      PMCID： PMC3437540          DOI： 10.4161/cbt.6.5.4431

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  37 in total

1.  Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study.

Authors:  A Bogdanov; E Marecos; H C Cheng; L Chandrasekaran; H C Krutzsch; D D Roberts; R Weissleder
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.

Authors:  Randolph S Watnick; Yi-Ning Cheng; Annapoorni Rangarajan; Tan A Ince; Robert A Weinberg
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

3.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

Authors:  B Jiménez; O V Volpert; S E Crawford; M Febbraio; R L Silverstein; N Bouck
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.

Authors:  W M Miao; W L Seng; M Duquette; P Lawler; C Laus; J Lawler
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

Review 5.  The functions of thrombospondin-1 and-2.

Authors:  J Lawler
Journal:  Curr Opin Cell Biol       Date:  2000-10       Impact factor: 8.382

Review 6.  The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development.

Authors:  J C Adams; R P Tucker
Journal:  Dev Dyn       Date:  2000-06       Impact factor: 3.780

7.  ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.

Authors:  Joshua C Anderson; J Robert Grammer; Wenquan Wang; L Burton Nabors; Jack Henkin; Jerry E Stewart; Candece L Gladson
Journal:  Cancer Biol Ther       Date:  2007-03-26       Impact factor: 4.742

8.  Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.

Authors:  Frank K Reiher; Olga V Volpert; Benilde Jimenez; Susan E Crawford; Colin P Dinney; Jack Henkin; Fortuna Haviv; Noel P Bouck; Steven C Campbell
Journal:  Int J Cancer       Date:  2002-04-10       Impact factor: 7.396

9.  Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Authors:  Olga V Volpert; Tetiana Zaichuk; Wei Zhou; Frank Reiher; Thomas A Ferguson; P Michael Stuart; Mohammad Amin; Noel P Bouck
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

Review 10.  Models for angiogenesis in gliomas.

Authors:  Roland H Goldbrunner; Martin Bendszus; Jörg-Christian Tonn
Journal:  Cancer Treat Res       Date:  2004
View more
  1 in total

1.  Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma.

Authors:  Jamie L Fox; Michael Dews; Andy J Minn; Andrei Thomas-Tikhonenko
Journal:  RNA       Date:  2012-12-18       Impact factor: 4.942
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.